InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.
Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes. In addition to its lead program, InflaRx is developing complementary C5a receptor antagonists and novel anti‐inflammatory antibodies in earlier stages of development. The company’s research efforts leverage proprietary antibody engineering and target validation platforms to identify and optimize molecules with high specificity and favorable safety profiles.
Founded in 2007, InflaRx is headquartered in Jena, Germany, with a subsidiary in Bernardsville, New Jersey. The company maintains a global footprint by collaborating with academic institutions, contract research organizations and key opinion leaders across Europe and North America. InflaRx completed its initial public offering on the Nasdaq Global Market in 2017, reflecting its commitment to advancing innovative therapies from bench to bedside.
Under the leadership of Chief Executive Officer Michael Ernst, M.D., InflaRx is supported by a management team with extensive experience in immunology, drug development and commercial strategy. The company continues to expand its clinical development capabilities as it works toward regulatory milestones and potential partnerships to bring its anti‐C5a therapies to patients worldwide.
AI Generated. May Contain Errors.
